Corvus Pharmaceuticals Files 8-K

TL;DR

CRVS filed an 8-K on Dec 18 - check for material updates.

AI Summary

Corvus Pharmaceuticals, Inc. filed an 8-K on December 18, 2024, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. Specific details regarding financial performance or significant corporate actions beyond the filing type are not elaborated in this excerpt.

Why It Matters

This 8-K filing indicates that Corvus Pharmaceuticals, Inc. is making disclosures to the SEC, which could include material information relevant to investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report, which typically contains routine disclosures rather than immediate, high-impact events.

Key Players & Entities

• Corvus Pharmaceuticals, Inc. (company) — Registrant
• December 18, 2024 (date) — Date of earliest event reported
• 0001558370-24-016343 (filing_id) — Accession Number
• Delaware (jurisdiction) — State of Incorporation
• 863 Mitten Road, Suite 102, Burlingame, CA 94010 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, Par Value $0.0001 per share CRVS Nasdaq Global Market
• $12.7 million — roceeds to the Company of approximately $12.7 million. Soquelitinib Interim Data from the At

Filing Documents

• crvs-20241218x8k.htm (8-K) — 110KB
• crvs-20241218xex99d1.htm (EX-99.1) — 100KB
• crvs-20241218x8k006.jpg (GRAPHIC) — 25KB
• crvs-20241218x8k007.jpg (GRAPHIC) — 27KB
• crvs-20241218xex99d1001.jpg (GRAPHIC) — 5KB
• crvs-20241218xex99d1002.jpg (GRAPHIC) — 42KB
• crvs-20241218xex99d1003.jpg (GRAPHIC) — 44KB
• 0001558370-24-016343.txt ( ) — 596KB
• crvs-20241218.xsd (EX-101.SCH) — 3KB
• crvs-20241218_lab.xml (EX-101.LAB) — 15KB
• crvs-20241218_pre.xml (EX-101.PRE) — 10KB
• crvs-20241218x8k_htm.xml (XML) — 5KB

01. Regulation FD

Item 7.01. Regulation FD. On December 18, 2024, Corvus Pharmaceuticals, Inc. (the "Company") issued the press release furnished as Exhibit 99.1 hereto.

01. Other Events

Item 8.01. Other Events. On December 18, 2024, the Company announced interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The Company also announced that Samlyn Capital, a holder of warrants to purchase 3,633,978 shares of common stock of the Company, has delivered exercise notices with respect to all of its warrants in advance of the June 30, 2025 expiration date, which is expected to result in cash proceeds to the Company of approximately $12.7 million. Soquelitinib Interim Data from the Atopic Dermatitis Phase 1 Clinical Trial The Company reported complete results from Cohort 1 of the trial, which includes 16 patients (12 that received soquelitinib 100 mg oral twice per day and four that received placebo) with follow up at 28 days and at 58 days. At 58 days, two patients in the soquelitinib group were not available for follow up. See Table 1 below for patient characteristics. Table 1: Cohort 1 Patient Characteristics Soquelitinib Placebo (N=12) (N=4) Age, mean (range), yrs 46.3 (30–66) 50.5 (32–62) Gender, male n (%) 7 (58.3) 4 (100) Race/ethnicity, n (%) Asian 2 (16.7) 0 (0) Black or African American 6 (50) 4 (100) White 3 (25) 0 (0) Hispanic or Latino 1 (8.3) 0 (0) Baseline EASI, mean (range) 20.4 (15.0–46.6) 18.5 (14.9–24.8) Baseline IGA, mean (range) 3.0 (2–4) 3.3 (3–4) Prior AD therapies, n (%) Topical Corticosteroids 11 (91.7) 4 (100) Systemic therapies 3 (25) 2 (50) Concomitant topical steroids 0 (0) 1 (25) The mean baseline EASI and IGA scores for soquelitinib patients were 20.4 and 3.0, respectively, compared to an EASI score of 18.5 and an IGA score of 3.3 for placebo patients. All soquelitinib patients discontinued topical corticosteroids prior to enrollment, while one placebo patient continued topical corticosteroid treatment. All patients, except the one placebo, discontin

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements, including statements related to the potential safety and efficacy of soquelitinib; expected cash proceeds from the exercise of warrants; and the Company's conduct of, enrollment in and timing of clinical trials. All statements other than statements of historical fact contained in this Current Report on Form 8-K are forward-looking statements. These statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "seek," "will," "may" or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company's Quarterly Report on Form 10-Q for the three months ended September 30, 2024, filed with the Securities and Exchange Commission on November 12, 2024, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company's ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates; the accuracy of the Company's estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company's ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the Unit

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Corvus Pharmaceuticals, Inc. dated December 18, 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL Document). The information furnished in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CORVUS PHARMACEUTICALS, INC. Date: December 18, 2024 By: /s/ Leiv Lea Leiv Lea Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR